The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice.
Gouty arthritis is caused by the deposition of monosodium urate (MSU) crystals in joints. Despite many treatment options for gout, there is a substantial need for alternative treatments for patients unresponsive to current therapies. Tyrosine kinase inhibitors have demonstrated therapeutic benefit i...
Main Authors: | Laurent L Reber, Philipp Starkl, Bianca Balbino, Riccardo Sibilano, Nicolas Gaudenzio, Stephan Rogalla, Steven Sensarn, Dongmin Kang, Harini Raghu, Jeremy Sokolove, William H Robinson, Christopher H Contag, Mindy Tsai, Stephen J Galli |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5628843?pdf=render |
Similar Items
-
Imatinibe mesilato no Brasil Imatinibe mesylate in Brazil
by: Marcos Lima
Published: (2005-09-01) -
Imatinib mesylate-induced palmoplantar keratoderma
by: Niharika Jha, et al.
Published: (2021-01-01) -
Periorbital edema secondary to imatinib mesylate
by: Collin M McClelland, et al.
Published: (2010-05-01) -
Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01) -
Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01)